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Abstract
Objective: To determine whether information from genetic risk variants for diabetes is associated with cardiovascular
events incidence.
Methods: From the about 30 known genes associated with diabetes, we genotyped single-nucleotide polymorphisms at
the 10 loci most associated with type-2 diabetes in 425 subjects from the MASS-II Study, a randomized study in patients
with multi-vessel coronary artery disease. The combined genetic information was evaluated by number of risk alleles for
diabetes. Performance of genetic models relative to major cardiovascular events incidence was analyzed through Kaplan-
Meier curve comparison and Cox Hazard Models and the discriminatory ability of models was assessed for cardiovascular
events by calculating the area under the ROC curve.
Results: Genetic information was able to predict 5-year incidence of major cardiovascular events and overall-mortality in
non-diabetic individuals, even after adjustment for potential confounders including fasting glycemia. Non-diabetic
individuals with high genetic risk had a similar incidence of events then diabetic individuals (cumulative hazard of 33.0
versus 35.1% of diabetic subjects). The addition of combined genetic information to clinical predictors significantly
improved the AUC for cardiovascular events incidence (AUC=0.641 versus 0.610).
Conclusions: Combined information of genetic variants for diabetes risk is associated to major cardiovascular events
incidence, including overall mortality, in non-diabetic individuals with coronary artery disease.
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Introduction
Type-2 diabetes mellitus (T2DM) is a common disease present
in about 200 million individuals around the world and its
prevalence has been increasing [1]. Genome-wide association
studies (GWASs) have identified about 30 susceptibility genes for
T2DM in different populations [2,3,4,5,6,7,8], of which the most
important (based on estimated size effect) are PPARG, SLC30A8,
HHEX, TCF7L2, KCNJ11, IGFBP-2, CDKAL1, CDKN2A/B and
FTO. Nevertheless, these polymorphisms have, individually, only
small effects on T2DM risk, with odds ratios around 1.3.
Considering that genetic susceptibility for complex diseases such
as T2DM is caused by multiple genetic variants, predictive tools
based on information from a single genetic polymorphism will be
of limited value [9]. Accordingly, studies have found that the
predictive value for T2DM diagnosis can be improved by
combining multiple common low-risk variants [9,10,11,12,13,
14,15]. The importance of predicting the risk of an individual to
present diabetes is related to the possibility of early diagnosis and
the potential avoidance of T2DM-related complications, particu-
larly cardiovascular disease. Despite this fact, fewer studies have
concentrated efforts in determining whether knowledge of T2DM-
associated SNPs in individuals with established cardiovascular
disease can be of any good. Recently, a study have shown the
association of polymorphism rs7903146 of TCF7L2 gene and
cardiovascular events incidence [16], but it did not assess whether
the combination of multiple risk variants beyond TCF7L2 is useful
in predicting cardiovascular events.
In this study, we tested whether the combination of multiple
genetic risk variants known to predict T2DM can be used to
predict cardiovascular events in individuals with chronic coronary
artery disease.
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Study population
The MASS II trial was a prospective, randomized and
controlled clinical trial that was designed to compare medical
treatment, percutaneous coronary intervention (PCI), and coro-
nary artery bypass graft (CABG) surgery in patients with stable
multi-vessel CAD and preserved left ventricular function. Briefly,
individuals who were indicated for myocardial revascularization
were evaluated from May, 1995 to May, 2000 and were randomly
assigned to one of the three therapeutic groups. The inclusion
criteria were symptomatic multi-vessel coronary disease, preserved
left ventricular function, and the presence of coronary lesions (70%
of stenosis) amenable both to angioplasty and surgery. Enrolled
patients were followed up for five years and were assessed for
cardiovascular events (overall-mortality, myocardial infarction,
PCI, CABG) or the combination of them. The diagnosis of
diabetes mellitus was based on previous treatment for diabetes or
ADA criteria [17]. Individuals that did not meet criteria for
diabetes according ADA were included in the non-diabetic group
at baseline. Other studies that used this same population for
similar analysis have been previously published [18,19,20,21].
We genotyped single-nucleotide polymorphisms (SNP) at 10 loci
associated with type-2 diabetes in 425 subjects from the MASS-II
Study and a 5-years follow-up was performed. Other 186
individuals who were initially randomized were excluded because
incomplete genotypic information from all studied genetic markers
was available. A comparison of baseline characteristics between
included and excluded individuals was performed and there were
no significant differences between them (See Table S1 in
Supplementary Material). All subjects gave written informed
consent, and the Ethics Committee of the Heart Institute of the
University of Sa ˜o Paulo-Brazil approved the study. All procedures
were performed in accordance with the Helsinki Declaration of
1975 (revised 1983).
Selection of SNPs, risk alleles, and genotyping
A large-scale meta-analysis performed for T2DM in populations
of European ancestry [4] reported consistent associations between
T2DM and ten SNPs: KCNJ11 rs5219, PPARG rs1801282,
TCF7L2 rs7903146, SLC30A8 rs13266634, HHEX rs1111875,
CDKAL1 rs7754840, IGFBP2 rs4402960, FTO rs8050136,
CDKN2A/B rs10811661 and rs9300039. We selected these genetic
markers for the present study.
Genomic DNA was extracted from peripheral blood leukocytes
by means of a standard salting-out procedure. Genotyping assays
were run as submicroliter PCR-based assays on array tape, which
is a continuous plastic tape that is used in conjunction with a
flexible configuration of dispensing, pipetting, sealing and
detection modules manufactured by Douglas Global Array.
Thermocycling was performed in sealed master tape in aqueous
immersion in the thermocycler. A modified allele-specific PCR
assay as described by Myakishev [22] was used. We obtained an
average genotyping success rate of more than 95% and an average
genotyping accuracy of 100% by regenotyping 32 samples. All
SNPs were in Hardy–Weinberg equilibrium (P.0.001).
For the analysis of the effects of the combined genetic variants,
we used an additive genetic model, i.e., the total number of risk
alleles (each individual could have 0,1, or 2 alleles, for a total of 20,
in 10 genes), which were significantly associated with diabetes. A
clinical model that contained only clinical variables associated with
mortality and re-infartion in MASS-II study (age, arterial
hypertension and previous myocardial infarction) was built by
the sum of Cox regression coefficient values of each variable
multiplied by 10, and rounded to the nearest integer (See Table S2
with these values in Supplemental Material). The incremental
value of combining genetic information to the clinical risk factors
model was also evaluated.
Statistical Analysis
Chi-square tests, t-tests, and analysis of variance were used for
baseline comparisons. For multiple comparisons, a more restrictive
significance threshold for p value was used by a Bonferroni’s
correction for multiple comparisons. Long-term survival compar-
isons were conducted for the entire study group and for the
subgroups of diabetic and non-diabetic patients at baseline. Cox
regression was used to estimate the prospective association of these
variables with each of the endpoints (death, myocardial infarction,
and recurrent ischemia requiring revascularization), as well as the
combined endpoint after 5-year follow-up. Survival curves were
calculated with the Kaplan-Meier method, and differences
between the curves were evaluated with the log-rank statistic. In
order to evaluate the models performance, a receiver operating
characteristic (ROC) curve was built and the area under ROC
curve (AUC or C statistics) was used to measure the discriminative
power. C statistic for the clinical model and the genetic
information added to the clinical model were compared by using
the ROCKIT software (http://www-radiology.uchicago.edu/krl/
KRL_ROC/software_index6.htm). Statistical analyses were per-
formed with the use of SPSS software, version 13.0.
Results
In the MASS-II population, a total of 425 individuals were
genotyped for all of the ten studied SNPs, from whom 134 had
diabetes (31.5%). Clinical characteristics of participants at baseline
are provided in Table 1 and characteristics of the 10 risk loci are
shown in Supplemental Material (Table S3). Diabetic and non-
diabetic subjects differed in relation to hypertension prevalence.
Therefore, all further tests were corrected for this variable as a
possible confounder. Only TCF7L2 gene was singly associated with
T2DM in preliminary analysis, however, after correction for
multiple comparisons and considering a p value more restrictive
(p,0.005), TCF7L2 polymorphism did not reach statistical
significance. Initially, we evaluated the association between the
Table 1. Clinical characteristics of diabetic individuals and
non-diabetics from MASS-II Study.
Diabetes
(n=134)
Non-diabetic
(n=291)
P
value
Age (years) 60.4068.82 59.3169.36 0.256
Gender (male %) 63.4% 69.1% 0.250
BMI (kg/m
2) 27.6864.44 26.9864.00 0.109
Total cholesterol (mg/dl) 219.23650.56 226.31650.27 0.181
HDL-cholesterol (mg/dl) 38.19611.27 36.7669.86 0.200
LDL-cholesterol 143.78645.67 150.93644.34 0.141
Triglycerides (mg/dl) 204.786145.07 190.266105.24 0.247
Hypertension (%) 67.9% 54.3% 0.008
Smoking (%) 28.4% 35.1% 0.173
Previous MI (%) 42.5% 46.7% 0.419
Three-vessel disease (%) 56.7% 54.6% 0.689
Data are shown in mean 6 SD or percentage.
doi:10.1371/journal.pone.0016341.t001
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population and this association was significant (See Supplementay
Material, Tables S4 and S5).
In order to evaluate if T2DM risk alleles were associated with
cardiovascular events incidence in the MASS-II population, we
performed a division of individuals in three groups based on the
number of risk alleles tertiles: lower risk (0 to 11 risk alleles), middle
(12 or 13 alleles) and higher (14 or more risk alleles). Although
diabetic individuals had a higher incidence of cardiovascular
events than non-diabetics (35.1% vs 24.4, p=0.022), it was
observed that genetic tertiles were not associated with the
composite end point of cardiovascular events (cardiac death,
myocardial infarction, and refractory angina requiring revascu-
larization or new percutaneous coronary intervention – PCI) in
individuals with already established diabetes. Interestingly, how-
ever, individuals with higher number of alleles were associated
with a significantly higher incidence of cardiovascular events in
non-diabetic individuals (Kaplan-Meier curve analysis shown in
Figure 1). In addition, there were no significant differences
between the estimates of the probability of survival from diabetic
individuals and non-diabetic individuals in the higher genetic risk
group (p value.0.4). After 5-years of follow-up, diabetic
individuals presented a cumulative incidence of the combined
end-point of 35.1% against non-diabetic individuals in the third
tertile risk group that presented 33.0% (Table 2). To corroborate
these findings, there was significant interaction between diabetes
and risk alleles for combined end-points (p value=0.029). These
data suggest that non-diabetic individuals whom have high
number of risk alleles have similar outcomes as individuals with
already established diabetes.
Moreover, resembling the already established behavior of
diabetic individuals regarding treatment options for chronic
coronary artery disease [23], non-diabetic individuals with more
risk alleles showed similar treatment-specific patterns of long-term
response. Non-diabetic individuals with higher number of risk
alleles, as well as diabetic individuals, submitted to percutaneous
coronary interventions presented significantly higher event rates
than non-diabetic individuals with low risk, as shown in Figure 2A.
The p value for interaction between T2DM risk alleles and
treatment received was significant (,0.0001). Information regard-
ing diabetes or genetic risk polymorphims in non-diabetic
individuals was not able to long-term stratify individuals submitted
to CABG surgery or medical treatment (Figure 2B and 2C).
After multivariate adjustment of a Cox proportional hazards
model for several established risk factors for cardiovascular disease,
the number of risk alleles were significantly and independently
associated with cardiovascular events (p value,0.05). Interesting-
ly, even when fasting glycemia values were included as covariate in
the Cox proportional model, it remained significantly associated to
composite events incidence (Table 3). In addition, the number of
risk alleles was also independently associated to overall mortality (p
value=0.009). We also evaluated 250 patients who completed the
5-years follow up and from whom complete biochemical data was
available. Of these, 38 subjects became diabetic at the end of the
Figure 1. Kaplan-Meier Curves of combined T2DM risk alleles and composite cardiovascular end-point in non-diabetic individuals
separated by groups according to number of risk alleles tertiles and diabetic subjects after 5 years of follow-up. Note diabetic
individuals’ curves are similar to higher tertiles’ curves. P values to pairwise comparisons: Lower vs middle: p=0.052; lower vs higher: p=0.002; lower
vs diabetics: p=0.001; middle vs higher: p=0.178; middle vs diabetics: p=0.101; higher vs diabetics: p=0.870.
doi:10.1371/journal.pone.0016341.g001
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after 5-years follow-up), the number of risk alleles was also
associated with composite cardiovascular end points (p=0.035)
suggesting that the observed association was not entirely due to
diabetes emergence during the follow-up period in individuals with
more risk alleles.
Because it had already been shown that polymorphisms in
TCF7L2 gene were associated with cardiovascular events [16],
genotypic information from TCF7L2 was excluded from analysis to
assess whether the positive association of combined information
happened only because of TCF7L2 influence. Even when TCF7L2
data were excluded, the combined risk alleles remained signifi-
cantly associated with the composite cardiovascular end-point in
non-diabetic individuals (See Figure S1 in Supplemental Material)
and with all-cause mortality (p value=0.036).
The performance of the predictive risk models can be observed
by the ROC curves: if only clinical variables (combination of age,
arterial hypertension and previous myocardial infarction) were
used to predict cardiovascular events in the MASS-II population,
the AUC (C statistics) of this model would be relatively low
(AUC=0.61, p,0.0001). However, the addition of genetic
information significantly improved the clinical model’s perfor-
mance (Figure 3): AUC increased to 0.641 (p=0.03 for
comparison between the C statistic of both ROC curves).
Discussion
The results of our study provide additional information
regarding the importance of genetic risk variants for T2DM.
Our results extend previous by showing evidence that the
utilization of combined genetic information for T2DM risk may
still provide valuable information for cardiovascular events
prediction. To our knowledge, this is the first study to evaluate
the association between combined common genetic variants for
type 2 DM in the scenario of major cardiovascular events
incidence in chronic coronary artery disease.
Different from other studies where T2DM prediction was the
main outcome and the study samples were mainly composed by
individuals from the general population, we have explored the
potential use of information associated with inherited risk for
diabetes, a major cardiovascular risk factor, in the somehow more
constrained scenario of multi-vessel chronic coronary artery
disease. In this respect, the MASS-II Trial is an exquisite tool by
allowing for the test of this hypothesis in a sample of individuals
with established chronic coronary artery disease, prospectively
followed for 5-years. Our data suggest that risk alleles for T2DM
are also able to predict cardiovascular events incidence in non-
diabetic individuals. Moreover, the proposed genetic risk model
could also stratify non-diabetic individuals in risk strata thus
allowing one to identify non-diabetic individuals with similar risk
than diabetic individuals. This stratification was above and beyond
established cardiovascular risk factors. Interestingly, we were not
able to find similar results in diabetic individuals, suggesting that
once diabetes is established, cardiovascular risk is high, regardless
of the underlying causes of this derangement. Even after
adjustment for established risk factors for cardiovascular disease,
the risk alleles were independently associated with cardiovascular
events (HR for increase of each allele: 1.16, p=0.022). Similar
results were found regarding all-cause mortality after decom-
pounding the end points in non-diabetic individuals. Our data
suggest that a subgroup of individuals potentially harboring an
increased risk of becoming diabetic could be targeted for more
Table 2. Number of composite cardiovascular events and
cumulative hazard in diabetic subjects and non-diabetic
subjects according to number of risk alleles tertiles.
Number of
events
Cumulative
Hazard (%) P value
P value for
interaction
Non-diabetic individuals
Lower tertile
Middle tertile
Higher tertile
13
27
31
14.4
25.2
33.0
0.004* 0.0291
Diabetic individuals 47 35.1 0.022{
(*) P value for comparison between tertiles and diabetic subjetcs;
({) P value for comparison between non-diabetic versus diabetic subjetcs;
(1) p value for interaction analysis between diabetes and T2DM risk alleles.
doi:10.1371/journal.pone.0016341.t002
Figure 2. Kaplan-Meier curves for composite cardiovascular end-point in non-diabetic subjects separated by groups according to
number of risk alleles tertiles and diabetic individuals, in accordance with the kind of treatment received (A - angioplasty, B -
medical therapy or C - CABG). Note for patients submitted to angioplasty, diabetic subjects and higher tertile non-diabetic individuals had higher
end-point incidence.
doi:10.1371/journal.pone.0016341.g002
Genetic Variants of Diabetes and Coronary Disease
PLoS ONE | www.plosone.org 4 January 2011 | Volume 6 | Issue 1 | e16341precocious and rigorous preventive efforts, similar to what is
advocated for diabetic individuals with coronary artery disease.
Previously, Haffner et al. [24] have demonstrated that incidence
rates of myocardial infarction in non-diabetic individuals with
prior myocardial infarction were comparable to diabetic subjects
without previous myocardial infarction. Interestingly, in our work,
individuals with more risk alleles had rates of cardiovascular events
comparable to those who had diabetes. In addition, data from the
BARI study [25] have found that diabetic patients with multi-
vessel coronary artery disease who underwent coronary revascu-
larization therapy with angioplasty had higher event rates than
those that underwent CABG or medical treatment. Similarly, in
our data, non-diabetic patients in the highest risk strata also had
this pattern according to the treatment option they were
randomized to. A significant interaction supports the explanation
that these two variables do not influence the cardiovascular
endpoints in an additive manner, i.e., the simultaneous influence
of the type of treatment (PCI, CABG or medical treatment) and
Table 3. Hazard ratio and 95% confidence interval (CI) for composite cardiovascular end-point and mortality according to each risk
allele in the entire population and in diabetic and non-diabetic individuals.*
Non-diabetic subjects Diabetic subjects Entire population
HR 95%CI P value HR 95%CI P value HR 95%CI P value
Composite Cardiovascular
events
Number of alleles 1.163 1.02–1.32 0.022 1.034 0.87–1.22 0.696 1.113 1.01–1.28 0.033
Number of alleles - no TCF7L2 1.125 0.99–1–29 0.084 1.049 0.88–1.26 0.594 1.104 0.99–1.22 0.061
Non-diabetic subjects Diabetic subjects Entire population
HR 95%CI P value HR 95%CI P value HR 95%CI P value
Mortality
Number of alleles 1.217 1.01–1.46 0.038 0.936 0.75–1.16 0.553 1.081 0.94–1.24 0.261
Number of alleles - no TCF7L2 1.145 0.95–1.38 0.163 0.925 0.74–1.16 0.493 1.034 0.90–1.19 0.638
(*) adjusted by age, gender, arterial hypertension, BMI, total cholesterol, HDL, LDL, triglycerides, previous MI, smoking and fasting glycemia.
doi:10.1371/journal.pone.0016341.t003
Figure 3. Discriminatory ability for composite cardiovascular events of risk alleles and clinical risk factors in non-diabetic
individuals. ROC Curves for cardiovascular events in the MASS-II population. Observe an increased area under ROC curves (AUC or C statistic) after
addition of information of combined risk alleles into clinical model for cardiovascular events. (*) Asymptotic significance: P value,0.00001. P values
for comparisons between clinical model and mixed model (clinical and genetic model) =0.03.
doi:10.1371/journal.pone.0016341.g003
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simple sum of these variables.
We did not observe any association between number of alleles
tertiles and cardiovascular risk factors at baseline in the studied
sample. It is thus reasonable to speculate that the observed
association between combined T2DM risk alleles and cardiovas-
cular events occurs due to elevations in glycemia, even in a
normal, fasting or postprandial, range. Indeed, a recent meta-
analysis confirmed the significant association between 2-hour
glucose levels after an oral glucose overload and incident
cardiovascular events [23]. Coutinho et al. carried out a meta-
analysis of 20 studies for a total of more than 90,000 non-diabetics
individuals and have found an exponential relationship between
the risk of cardiovascular events and both fasting and postload
plasma glucose levels. Such relationship was present at even below
diagnostic glycemia levels for diabetes, impaired fasting glycemia
or impaired glucose tolerance [23]. In addition, systematic
evaluation of databases such as deCODE have shown that this
relationship between glycemia and cardiovascular risk begins
within normal glycemia range, with a linear relationship and
shows no indication of a threshold [26]. These data support the
hypothesis that even non-diabetic levels of fasting and mainly
postprandial hyperglycemia are associated with cardiovascular
events incidence and could explain the reason why non-diabetic
individuals had similar cardiovascular events than diabetic
subjects. In addition, considering that the association of glucose
with CVD risk is well established, it would be quite possible that
fasting glucose may capture most of the risk conferred by the
genetic variants in non-diabetic individuals. Indeed, after includ-
ing this variable in the model, there was a reduction in the
magnitude of effects. Nevertheless, combined T2DM risk alleles
remained associated with composite cardiovascular end point and
all-cause mortality. In addition, even after exclusion of subjects
that became diabetics at end of follow-up period, the association
between cardiovascular events and T2DM risk alleles persisted.
Some potential limitations of our study should be acknowledged.
Sample size was relatively small. However, even a relatively small
sample size of non-diabetic subjects was able to provide a clear
understanding of the relative importance of combined genetic
information as a predictor of cardiovascular events due to the
relatively large effect size of the derived genetic model. On the other
hand, there were only a limited number of diabetic individuals and
one cannot exclude that this has led to reduced statistical power to
detect the association that we were able to describe in non-diabetic
individuals. The MASS-II clinical trial was designed for specific
purposes and this work was an observational study that used data
from MASS-II. Therefore, it is not possible to exclude that residual
unmeasured characteristics or confounding factors may influence
the results. In addition, considering the specific characteristics of the
studied population, the internal and external validation of results
may be limited, i.e. to extrapolate the results to population with
multivessel CAD with ventricular disfunction or even non-diabetic
individuals from the general population further studies will be
necessary. Moreover, there was a relatively high proportion of
missing data from the initial study population. Nevertheless, there
were no differences between groups of individuals included and
excluded in the analysis, therefore exclusion of subjects without
genotype data probably did not affect the results. To date, there are
approximately 30 risk variants associated with T2DM [6,8] and
only 10 polymorphisms were used in the present study. It is possible,
therefore, that if other variables were included in risk prediction
models, the results would be even more significant. Another
limitation is that we did not assess postprandial glicemia at baseline
in our study. Thus, it is possible that similar information could be
obtained through an oral glucose tolerance test at baseline. As a
result, this study is not able to confirm that the findings are a result
of hyperglycemia, or postprandial hyperglycemia, even in normal
levels. Neither, we can exclude that the genetic effect may be
captured by HbA1c or post-prandial/OGTT glycemic values.
Nevertheless, it is interesting to note that genetic tests may
potentially provide more time for the institution of secondary
prevention and do not require to be repeated periodically,
characteristics that may allow for the development of more cost-
effective management programs for this specific population.
In conclusion, combined information on genetic variants for
diabetes risk was associated with major cardiovascular events
incidence in non-diabetic individuals with coronary artery disease.
In addition, our data suggest that non-diabetic individuals with
higher number of T2DM risk alleles had an incidence of
cardiovascular events similar to individuals with established
diabetes. Other studies are necessary to confirm our results in
similar and different populations.
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Figure S1 Kaplan-Meier Curves of combined risk
alleles without TCF7L2 data and composite cardiovas-
cular end points in non-diabetic individuals separated
by groups according to number of alles tertiles after 5
years of follow-up. Even when TCF7L2 data were excluded
from analysis, the combined risk alleles remained significantly
associated with the composite cardiovascular end-point in non-
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